Page last updated: 2024-12-05

testosterone propionate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Testosterone Propionate: An ester of TESTOSTERONE with a propionate substitution at the 17-beta position. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

androgen : A sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5995
CHEMBL ID1170
CHEBI ID9466
SCHEMBL ID4044
MeSH IDM0021197

Synonyms (182)

Synonym
AC-12172
MLS002153796
smr000058348
BRD-K90553655-001-03-6
AKOS015842719
androst-4-en-3-one, 17-(1-oxopropoxy)-, (17.beta.)-
17-propionyl-17beta-hydroxyandrost-4-en-3-one
LMST02020076
testosterone-17.beta.propionate
androteston
testormol
tostrin
homandren (amps)
andrusol-p
telipex
testolets
bio-testiculina
synandrol
androtest p
neo-hombreol
testosid
hormoteston
nsc9166
pantestin
testaform
testoxyl
solvotest
testonique
testex
nasdol
testosterone-17-propionate
uniteston
synerone
testrex
testodet
testosterone, propionate
masenate
nsc 9166
wln: l e5 b666 ov mutj a e fo52 -b&aef
testodrin
agovirin
orchiol
androgen
vulvan
testosterone-17.beta.-propionate
aquaviron
testosteron propionate
androsteston
andronate
okasa-mascul
androlon
oreton propionate
testogen
orchistin
sterandryl
nsc-9166
androst-4-en-3-one, 17-(1-oxopropoxy)-(17.beta.)-
propiokan
enarmon
PRESTWICK_432
NCGC00016254-01
BPBIO1_000356
NCGC00179602-01
PRESTWICK3_000401
PRESTWICK2_000401
BSPBIO_000322
57-85-2
testosterone propionate
C08158
testosterone propionate, solid
DB01420
testex (tn)
D00959
testosterone propionate (jp17/usp)
delta(sup 4)-androstene-17-beta-propionate-3-one
androst-4-en-3-one, 17-(1-oxopropoxy)-, (17beta)-
testosterone-17beta propionate
testosteroni propionas
androst-4-en-3-one, 17beta-hydroxy-, propionate
17beta-hydroxyandrost-4-en-3-one propionate
primotestone
testosterone-17beta-propionate
ccris 575
17beta-hydroxy-4-androsten-3-one 17-propionate
17beta-hydroxyandrost-4-en-3-one-17beta-propionate
einecs 200-351-1
17beta-(propionyloxy)androst-4-en-3-one
ai3-26378
testosterone-17-beta-propionate
PRESTWICK0_000401
SPBIO_002261
PRESTWICK1_000401
(17beta)-3-oxoandrost-4-en-17-yl propionate
androst-4-en-3-one, 17-(1-oxopropoxy)-(17-beta)-
chebi:9466 ,
testosterone 17.beta.-propionate
CHEMBL1170 ,
testosterone propionate ciii
orchisterone
nrb-03689
testosteron 17-propionate
propionic acid (8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl ester
bdbm50215709
propionic acid 10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl ester
propionic acid 10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl ester(testosterone propionate)
HMS1569A04
[(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] propanoate
(17beta)-3-oxoandrost-4-en-17-yl propanoate
STK801834
AKOS005622513
HMS2096A04
cas-57-85-2
dtxcid7016515
NCGC00255481-01
dtxsid9036515 ,
tox21_302270
T0028
tox21_110330
HMS2272K06
BCP0726000215
testosterone propionate (agovirin)
unii-wi93z9138a
testosterone propionate [usp:jan]
wi93z9138a ,
testoviron (ampule)
testosterone propionate [mi]
testosterone propionate [ep monograph]
testosterone propionate [usp impurity]
testosterone propionate [who-dd]
testosterone propionate [mart.]
testosterone propionate [vandf]
testosteroni propionas [who-ip latin]
testosterone propionate [who-ip]
testosterone propionate [jan]
testosterone propionate [usp monograph]
testosterone propionate [orange book]
testosterone propionate [green book]
gtpl7100
CCG-220401
BBL029912
SCHEMBL4044
NCGC00179602-03
tox21_110330_1
PDMMFKSKQVNJMI-BLQWBTBKSA-N
CS-4905
testosteron-17-propionat
W-105436
androst-4-en-3-one, 17-(1-oxopropoxy)-, (17b)-
testosterone propionate, british pharmacopoeia (bp) reference standard
17.beta.-(propionyloxy)androst-4-en-3-one
.delta.4-androstene-17.beta.-propionate-3-one
17-(1-oxopropoxy)androst-4-en-3-one, (17.beta.)-
17.beta.-hydroxyandrost-4-en-3-one, propionate
3-oxoandrost-4-en-17-yl propionate, (17.beta.)-
androst-4-en-3-one, 17.beta.-hydroxy-, propionate
AC-33160
HY-B1269
testosterone (propionate)
testosterone propionate, tested according to ph.eur.
testosterone propionate, united states pharmacopeia (usp) reference standard
testosterone propionate, european pharmacopoeia (ep) reference standard
testosterone propionate for system suitability, european pharmacopoeia (ep) reference standard
testosterone propionate 1.0 mg/ml in acetonitrile
HMS3713A04
VS-09499
(1s,3as,3br,9ar,9bs,11as)-9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl propanoate
Q10354588
NCGC00179602-06
testosterone propionate (usp:jan)
testoviron (amps)
(17beta)-17-(1-oxopropoxy)androst-4-en-3-one
testosterone propionate (ep monograph)
textes depot
testosterone propionate (usp impurity)
testosterone propionate (mart.)
testosterone propionate (usp monograph)
perandren (amp.)
orchisterone-p
3-oxoandrost-4-en-17beta-yl propanoate
testosterone 17beta-propionate
17-(1-oxopropoxy)-(17-beta)-androst-4-en-3-one
testosterone 17-propionate

Research Excerpts

Actions

ExcerptReferenceRelevance
"Testosterone propionate injection can increase albumin level, shorten the time of mechanical ventilation, and improve the condition and prognosis of patients with sepsis."( [Effect of testosterone propionate on condition and prognosis of sepsis patients].
Cai, W; Li, D; Li, Y; Ma, L; Shi, S; Wen, J; Yan, R; Zhang, Q; Zhang, Y, 2020
)
2.39

Treatment

Testosterone propionate treatment reduced proenkephalin expression in the diagonal band of Broca, the caudal preoptic area, and the bed nucleus of the stria terminalis. Treatment with TP in castrated males resulted in plasma testosterone levels similar to males following mating.

ExcerptReferenceRelevance
"Testosterone propionate treatment in both doses resulted in reduction (P < 0.01) in testicular weight and increase (P < 0.01) in weight of vesicular gland, paraprostate and proprostate glands."( Effect of long-term testosterone propionate or human chorionic gonadotrophin administration on reproductive glands in adult male rabbits.
Abdel-Raouf, M; Hussein, HA, 2015
)
1.46
"Testosterone propionate treatment reduced proenkephalin expression in the diagonal band of Broca, the caudal preoptic area, and the bed nucleus of the stria terminalis."( Effect of testosterone and season on proenkephalin messenger RNA expression in the preoptic area of the hypothalamus in the ram.
Clarke, IJ; Mariani, M; Scott, CJ; Tilbrook, AJ, 2003
)
1.04
"Testosterone propionate treatment induced a significant increase of L-PGDS expression in the epididymis of castrated rats."( Expression and regulation of lipocalin-type prostaglandin d synthase in rat testis and epididymis.
Ma, H; Ma, XH; Mills, N; Ni, H; Yang, ZM; Zhu, H, 2004
)
1.04
"Treatment with testosterone propionate (TP) in castrated males resulted in plasma testosterone levels similar to males following mating."( Newly proliferated cells in the adult male amygdala are affected by gonadal steroid hormones.
Fowler, CD; Freeman, ME; Wang, Z, 2003
)
0.66

Toxicity

ExcerptReferenceRelevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" esculenta tuber extracts provide potentially safe nutraceutical if applied in the management of benign prostate hyperplasia based on a rat model."( Safety profile of colocasia esculenta tuber extracts in benign prostate hyperplasia.
Agu, PC; Aja, PM; Ajayi, CO; Ifie, JE; Munezero, J; Namale, N; Okoboi, J; Ssedyabane, F; Tusubira, D, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" (-)-18a has very good pharmacokinetic properties, including bioavailability in rat (F > 50%), and is currently under evaluation in phase I clinical trials."( Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.
Alvey, L; Blanqué, R; Deprez, P; Feyen, J; Fletcher, S; Guédin, D; Hebbe, S; Housseman, C; Jary, H; Klaassen, H; Lefrançois, JM; Manioc, M; Minet, D; Namour, F; Nique, F; Peixoto, C; Robin-Jagerschmidt, C; Triballeau, N; Van Beeck, K; Van der Aar, E, 2012
)
0.38
" The administration of these substances to animals is usually made through an intra-muscular pathway with the steroid under its ester form for a higher bioavailability and a longer lasting effect."( Ultra high performance liquid chromatography/tandem mass spectrometry based identification of steroid esters in serum and plasma: an efficient strategy to detect natural steroids abuse in breeding and racing animals.
Bichon, E; Bonnaire, Y; Cesbron, N; Dervilly-Pinel, G; Hanganu, F; Kaabia, Z; Le Bizec, B; Popot, MA, 2013
)
0.39
" EC508 might offer significant advantages in indications like fertility control and HRT based on its high oral bioavailability and lack of hepatic estrogenicity."( A prodrug design for improved oral absorption and reduced hepatic interaction.
Ahmed, G; Elger, W; Meece, F; Nair, HB; Nickisch, K; Schneider, B; Wyrwa, R, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" At the dosage levels used herein, V + TP-treated male offspring had less well-developed nipples as infants and adults and a lower incidence of ectopic testis than did the V group."( Interactive effects of vinclozolin and testosterone propionate on pregnancy and sexual differentiation of the male and female SD rat.
Gray, LE; LeBlanc, GA; Wolf, CJ, 2004
)
0.59
" Although all the androgen-responsive organ weights were increased significantly at dosages of 100 and 500 microg kg(-1) day(-1), the serum alpha2u-globulin level was increased significantly only at a dosage of 500 microg kg(-1) day(-1)."( Changes in serum alpha2u-globulin levels in castrated male rats treated with testosterone propionate in a Hershberger assay.
Mitoma, H; Takeyoshi, M; Yamasaki, K,
)
0.36
" After oral dosing in a rat atrophied levator ani muscle model, (7R,7aS)-10b demonstrated efficacy at restoring levator ani muscle mass to that of intact controls and exhibited >50-fold selectivity for muscle over prostate."( Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold.
An, Y; Beehler, BC; Fura, A; Golla, R; Grover, GJ; Hamann, LG; Huang, Y; Krystek, SR; Kuhns, JE; Lupisella, JA; Malley, MF; Ostrowski, J; Robl, JA; Sack, JS; Salvati, ME; Seethala, R; Sleph, PG; Sun, C; Wang, TC, 2006
)
0.33
" Sprague Dawley rats were dosed by gavage with 0, 31."( Prochloraz inhibits testosterone production at dosages below those that affect androgen-dependent organ weights or the onset of puberty in the male Sprague Dawley rat.
Blystone, CR; Furr, J; Gray, LE; Howdeshell, KL; Lambright, CS; Leblanc, GA; Ryan, BC; Wilson, VS, 2007
)
0.34
"Eight prenatally androgenized (PA) and 5 control female rhesus monkeys of similar age, body weight and body mass index received an oral placebo daily for 6-7 months followed, after at least 90 days, by daily oral dosing with pioglitazone (3mg/kg) for an additional 6-7 months."( Pioglitazone improves insulin action and normalizes menstrual cycles in a majority of prenatally androgenized female rhesus monkeys.
Abbott, DH; Bird, IM; Bruns, CM; Dumesic, DA; Goodfriend, TL; Kemnitz, JW; Zhou, R,
)
0.13
" In a standard castrated male rat model, several compounds showed good anabolic activity on levator ani muscle, dissociated from the androgenic activity on ventral prostate, after oral dosing at 30 mg/kg."( Discovery of diarylhydantoins as new selective androgen receptor modulators.
Annoot, D; Clément-Lacroix, P; Deprez, P; Duval, E; Fleury, D; Guédin, D; Hebbe, S; Lefrançois, JM; Lemoullec, JM; Michoux, L; Minet, D; Mollat, P; Nique, F; Peixoto, C; Prangé, T; Robin-Jagerschmidt, C; Thauvin, M; Triballeau, N, 2012
)
0.38
" A dosage of 1 mg cyproterone acetate every second day for a period of 4 weeks induces a reduction of the relative total sebaceous gland volume of about 80% in intact mice."( The effect of a new antiandrogenic steroid, 6-chloro-17-HYDROXY-1α, 2α-methylenepregna-4,6-diene-3,20-dione acetate (cyproterone acetate) on the sebaceous glands of mice.
Elger, W; Neumann, F, 1966
)
0.24
" An appropriate dosage of TP could induce permanent anovulation in guinea pigs, making them a potential model for human polycystic ovary syndrome."( Expression of matrix metalloproteinases and ovarian morphological changes in androgenized cyclic female guinea pigs.
Li, JR; Shen, T; Shi, FX; Wang, YL; Wei, QW, 2016
)
0.43
" The main source of information on AASs, doses, and dosage patterns was the Internet (48."( [The medical aspect of using anabolic androgenic steroids in males attending gyms of Saint-Petersburg].
Babenko, AY; Lykhonosov, MP, 2019
)
0.51
" We conducted two-part studies to determine the optimal dosage and dosing cycle for efficient and stable induction of benign prostatic hyperplasia using testosterone undecanoate."( Comparative application of testosterone undecanoate and/or testosterone propionate in induction of benign prostatic hyperplasia in Wistar rats.
An, J; Kong, H, 2022
)
0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
steroid ester
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (75)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
pregnane X receptorRattus norvegicus (Norway rat)Potency56.23410.025127.9203501.1870AID651751
phosphopantetheinyl transferaseBacillus subtilisPotency17.78280.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency54.94103.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency51.52020.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency46.92390.173734.304761.8120AID1346859; AID1346924
USP1 protein, partialHomo sapiens (human)Potency15.84890.031637.5844354.8130AID504865
SMAD family member 3Homo sapiens (human)Potency46.92390.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency24.84460.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency22.57910.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency5.37780.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID588515; AID588516; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency68.58960.013326.981070.7614AID1346978
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency17.23970.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency2.37100.001022.650876.6163AID1224838
progesterone receptorHomo sapiens (human)Potency8.72460.000417.946075.1148AID1346784; AID1346795; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency20.18140.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency22.48960.000214.376460.0339AID588532; AID588533; AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency55.43420.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency20.35320.000817.505159.3239AID1159527; AID1159531; AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency38.07680.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency57.89590.375827.485161.6524AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency27.30600.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency7.59920.000229.305416,493.5996AID1259244; AID1259383; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080
GVesicular stomatitis virusPotency17.61470.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency27.91740.00108.379861.1304AID1645840
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency58.82840.001024.504861.6448AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency52.07110.001019.414170.9645AID588536; AID588537; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency19.96650.023723.228263.5986AID743222; AID743223
caspase-3Homo sapiens (human)Potency68.58960.013326.981070.7614AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency34.45480.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency68.58960.001628.015177.1139AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency48.96620.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency39.88130.057821.109761.2679AID1159526; AID1159528
cytochrome P450 2C19 precursorHomo sapiens (human)Potency10.00000.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency8.91250.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency112.20203.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency38.90900.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency54.94100.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency39.62560.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency13.27790.004611.374133.4983AID624296; AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.25890.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency0.00790.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.42160.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency25.71470.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency17.61470.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency68.58960.002319.595674.0614AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.42160.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
TAR DNA-binding protein 43Homo sapiens (human)Potency14.12541.778316.208135.4813AID652104
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency79.43283.981146.7448112.2020AID720708
GABA theta subunitRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency17.61470.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency17.61470.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Steroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)IC50 (µMol)0.05600.00200.98184.7300AID53381
Androgen receptorHomo sapiens (human)Ki0.00030.00020.42407.2000AID299694
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)1.90550.00101.979414.1600AID255211
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorMus musculus (house mouse)EC50 (µMol)0.00280.00040.00360.0061AID299695
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorHomo sapiens (human)Activity0.00150.00150.00960.0370AID705266; AID706411
Neuropeptide FF receptor 2Rattus norvegicus (Norway rat)Activity0.00150.00150.01200.0370AID706411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (245)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
steroid biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
androgen biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
glucocorticoid biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
sex differentiationSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
steroid metabolic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
hormone biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
progesterone metabolic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
MAPK cascadeAndrogen receptorHomo sapiens (human)
in utero embryonic developmentAndrogen receptorHomo sapiens (human)
regulation of systemic arterial blood pressureAndrogen receptorHomo sapiens (human)
epithelial cell morphogenesisAndrogen receptorHomo sapiens (human)
transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
signal transductionAndrogen receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAndrogen receptorHomo sapiens (human)
cell-cell signalingAndrogen receptorHomo sapiens (human)
spermatogenesisAndrogen receptorHomo sapiens (human)
single fertilizationAndrogen receptorHomo sapiens (human)
positive regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
positive regulation of gene expressionAndrogen receptorHomo sapiens (human)
male somatic sex determinationAndrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
intracellular receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
Leydig cell differentiationAndrogen receptorHomo sapiens (human)
multicellular organism growthAndrogen receptorHomo sapiens (human)
positive regulation of phosphorylationAndrogen receptorHomo sapiens (human)
positive regulation of MAPK cascadeAndrogen receptorHomo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of cell differentiationAndrogen receptorHomo sapiens (human)
negative regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIIAndrogen receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
regulation of developmental growthAndrogen receptorHomo sapiens (human)
animal organ formationAndrogen receptorHomo sapiens (human)
male genitalia morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell proliferationAndrogen receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationAndrogen receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAndrogen receptorHomo sapiens (human)
activation of prostate induction by androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
morphogenesis of an epithelial foldAndrogen receptorHomo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
prostate gland growthAndrogen receptorHomo sapiens (human)
prostate gland epithelium morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell differentiation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
mammary gland alveolus developmentAndrogen receptorHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
cellular response to steroid hormone stimulusAndrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusAndrogen receptorHomo sapiens (human)
cellular response to testosterone stimulusAndrogen receptorHomo sapiens (human)
seminiferous tubule developmentAndrogen receptorHomo sapiens (human)
non-membrane-bounded organelle assemblyAndrogen receptorHomo sapiens (human)
positive regulation of miRNA transcriptionAndrogen receptorHomo sapiens (human)
regulation of protein localization to plasma membraneAndrogen receptorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayAndrogen receptorHomo sapiens (human)
male gonad developmentAndrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayAndrogen receptorHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (75)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
steroid 17-alpha-monooxygenase activitySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
iron ion bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
oxygen bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
heme bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
17-alpha-hydroxyprogesterone aldolase activitySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
transcription cis-regulatory region bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
RNA polymerase II general transcription initiation factor bindingAndrogen receptorHomo sapiens (human)
transcription coactivator bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
chromatin bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityAndrogen receptorHomo sapiens (human)
nuclear receptor activityAndrogen receptorHomo sapiens (human)
G protein-coupled receptor activityAndrogen receptorHomo sapiens (human)
signaling receptor bindingAndrogen receptorHomo sapiens (human)
steroid bindingAndrogen receptorHomo sapiens (human)
androgen bindingAndrogen receptorHomo sapiens (human)
protein bindingAndrogen receptorHomo sapiens (human)
beta-catenin bindingAndrogen receptorHomo sapiens (human)
zinc ion bindingAndrogen receptorHomo sapiens (human)
enzyme bindingAndrogen receptorHomo sapiens (human)
ATPase bindingAndrogen receptorHomo sapiens (human)
molecular adaptor activityAndrogen receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAndrogen receptorHomo sapiens (human)
POU domain bindingAndrogen receptorHomo sapiens (human)
molecular condensate scaffold activityAndrogen receptorHomo sapiens (human)
estrogen response element bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (45)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
endoplasmic reticulum membraneSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
axonSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
neuronal cell bodySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
plasma membraneAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleoplasmAndrogen receptorHomo sapiens (human)
cytoplasmAndrogen receptorHomo sapiens (human)
cytosolAndrogen receptorHomo sapiens (human)
nuclear speckAndrogen receptorHomo sapiens (human)
chromatinAndrogen receptorHomo sapiens (human)
protein-containing complexAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (128)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID375626Myotropic activity in rat assessed as levator ani muscle weight by Hershberger assay relative to intact tissue2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID296858Stimulation of levator ani muscle weight in castrated immature Sprague-Dawley rat2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators.
AID189791Percentage of progressive tumors in postmenopausal rat model at 20 mg/kg dose1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
New aromatase inhibitors. Synthesis and biological activity of pyridyl-substituted tetralone derivatives.
AID84033Local subcutaneous administration (125 ug); Expressed as weight (mg)1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Antiandrogenic activity of a series of des-A-steroid derivatives.
AID299694Displacement of [3H]DHT from human androgen receptor in MDA453 cells2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators.
AID189784Percentage partial remission of tumors in postmenopausal rat model at 20 mg/kg dose1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
New aromatase inhibitors. Synthesis and biological activity of pyridyl-substituted tetralone derivatives.
AID706398Anabolic activity in sc dosed ORX rat model assessed as maximum effect on levator ani muscle weight administered 4 days relative to sham-treated control2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Discovery of diarylhydantoins as new selective androgen receptor modulators.
AID296859Stimulation of prostate weight in castrated immature Sprague-Dawley rat2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators.
AID249806Effect of compound (0.8 mg/kg) on androgen induced increase in ventral prostate weight2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
AID1457898Toxicity in orchidectomized Sprague-Dawley rat assessed as decrease in circulating LH levels at 1 mg/kg, sc administered once daily for 4 days measured after 14 days by ELISA
AID188943Initial tumor number in postmenopausal rat model at 20 mg/kg dose1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
New aromatase inhibitors. Synthesis and biological activity of pyridyl-substituted tetralone derivatives.
AID84029Local subcutaneous administration (125 ug); Expressed as weight (mg)1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Antiandrogenic activity of a series of des-A-steroid derivatives.
AID705260Anabolic activity in ORX rat model assessed as weight of levator ani muscle at 1 mg/kg/day, sc administered for 4 days2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID276465Stimulation of levator ani muscle weight Sprague-Dawley rat at 5 mg/kg, sc2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Synthesis and SAR of novel hydantoin derivatives as selective androgen receptor modulators.
AID705266Partial agonist activity at human androgen receptor expressed in HeLa cells co-expressing ARE by luciferase reporter gene based transactivation assay2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1457895Androgenic activity in orchidectomized Sprague-Dawley rat assessed as increase in weight of seminal vesicles at 1 mg/kg, sc administered once daily for 4 days
AID84037Local activity of untreated flank organ in hamster; Expressed as weight (mg)1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Antiandrogenic activity of a series of des-A-steroid derivatives.
AID296863Stimulation of levator ani muscle weight in castrated Sprague-Dawley rat2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID706190Ratio of binding affinity to human androgen receptor in inactive state to human androgen receptor in active state2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Discovery of diarylhydantoins as new selective androgen receptor modulators.
AID375620Myotropic activity in rat assessed as seminal vesicle weight by Hershberger assay relative to intact tissue2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1187603Anabolic activity in orchidectomized rat assessed as stimulation of bulbocavernosus/levator ani muscle weight treated subcutaneously once daily for 14 days by Hershberger assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
3-alkoxy-pyrrolo[1,2-b]pyrazolines as selective androgen receptor modulators with ideal physicochemical properties for transdermal administration.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID705256Anabolic activity in ORX rat model assessed as dose required for 50% activity on levator ani muscle po administered for 4 days2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.
AID1466587Induction of sexual behavior in castrated CD(SD)IGS rat assessed as pseudopregnancy rate at 3 mg/kg, sc qd for 21 days measured on day 18 to 21 relative to control2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate.
AID299700Effect on levator ani muscle weight in castrated rat at 0.3 mg/kg, sc after 14 days relative to intact rat2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators.
AID274618Selectivity for stimulation of levetor ani muscle over suppression of LH secretion in sc dosed castrated Sprague-Dawley rat2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold.
AID1187604Androgenic activity in orchidectomized rat assessed as stimulation of prostate weight treated subcutaneously once daily for 14 days by Hershberger assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
3-alkoxy-pyrrolo[1,2-b]pyrazolines as selective androgen receptor modulators with ideal physicochemical properties for transdermal administration.
AID1130857Androgenic activity in castrate rat assessed as ventrol prostate weight at 3 mg, sc qd for 7 days by autopsy analysis (Rvb = 17.5 +/- 0.41 mg)1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Syntheses and biological activities of 7 beta-methyl steroids.
AID189071Final tumor number in postmenopausal rat model at 20 mg/kg dose1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
New aromatase inhibitors. Synthesis and biological activity of pyridyl-substituted tetralone derivatives.
AID1130859Androgenic activity in castrate rat assessed as seminal vesicle weight at 3 mg, sc qd for 7 days by autopsy analysis (Rvb = 13.6 +/- 0.19 mg)1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Syntheses and biological activities of 7 beta-methyl steroids.
AID274613Stimulation of levator ani muscle growth in sc dosed castrated Sprague-Dawley rat2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold.
AID705265Ratio of binding affinity for human androgen receptor active state to human androgen receptor inactive state2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1128337Increase in seminal vesicle weight in orchidectomized Sprague-Dawley rat at 1 mg/kg, sc qd for 4 days relative to vehicle-treated control2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulators.
AID53381In vitro cytochrome P450 17A1 inhibition was assayed using the rapid acetic acid releasing assay (AARA), utilizing intact P450c17-expressing Escherichia coli or P450c17-LNCaP cells as the enzyme source.2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
AID194352Percentage change in tumor area in postmenopausal rat model at 20 mg/kg dose1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
New aromatase inhibitors. Synthesis and biological activity of pyridyl-substituted tetralone derivatives.
AID375619Myotropic activity in rat assessed as ventral prostate weight by Hershberger assay relative to intact tissue2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.
AID1457894Anabolic activity in orchidectomized Sprague-Dawley rat assessed as increase in levator ani muscle weight at 1 mg/kg, sc administered once daily for 4 days
AID1464248AUC (0 to 3 hrs) in rat at 3 mg, po2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
A prodrug design for improved oral absorption and reduced hepatic interaction.
AID276463Stimulation of prostate weight in Sprague-Dawley rat at 5 mg/kg, sc2006Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22
Synthesis and SAR of novel hydantoin derivatives as selective androgen receptor modulators.
AID189777Percentage of unchanged tumor size in postmenopausal rat model at 20.0 mg/kg dose1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
New aromatase inhibitors. Synthesis and biological activity of pyridyl-substituted tetralone derivatives.
AID706399Androgenic activity in sc dosed ORX rat model assessed as dose required to induce 50% effect on ventral prostate weight administered 4 days2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Discovery of diarylhydantoins as new selective androgen receptor modulators.
AID706402Anabolic activity in ORX rat model assessed as levator ani muscle weight at 1 mg/kg, sc administered 4 days relative to sham-treated control2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Discovery of diarylhydantoins as new selective androgen receptor modulators.
AID192338Percentage complete remission of tumors in postmenopausal rat model at 20 mg/kg dose1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
New aromatase inhibitors. Synthesis and biological activity of pyridyl-substituted tetralone derivatives.
AID299698Effect on prostate muscle weight in castrated rat at 0.3 mg/kg, sc after 14 days relative to intact rat2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators.
AID292761Anabolic activity assessed as stimulation of levator ani muscle weight in castrated immature Sprague-Dawley rat at 5 mg/day, sc by Hersherberger assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgen receptor modulators.
AID296855Stimulation of prostate weight in castrated immature Sprague-Dawley rat at 1 mg/day, sc2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators.
AID706397Androgenic activity in sc dosed ORX rat model assessed as maximum effect on ventral prostate weight administered 4 days relative to sham-treated control2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Discovery of diarylhydantoins as new selective androgen receptor modulators.
AID706401Androgenic activity in ORX rat model assessed as ventral prostate weight at 1 mg/kg, sc administered 4 days relative to sham-treated control2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Discovery of diarylhydantoins as new selective androgen receptor modulators.
AID192025In vivo ventral prostate weights in juvenile castrated rats treated with testosterone propionate (1 mg/kg)2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Synthesis and evaluation of 2'-substituted 4-(4'-carboxy- or 4'-carboxymethylbenzylidene)-N-acylpiperidines: highly potent and in vivo active steroid 5alpha-reductase type 2 inhibitors.
AID1128336Increase in prostate tissue weight in orchidectomized Sprague-Dawley rat at 1 mg/kg, sc qd for 4 days relative to vehicle-treated control2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulators.
AID299695Agonist activity at androgen receptor in mouse C2C12 cells by receptor transactivation assay2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators.
AID291286Stimulation of levator ani muscle weight in Sprague-Dawley rat at 0.3 mg/kg, sc after 14 days2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications.
AID1457896Androgenic activity in orchidectomized Sprague-Dawley rat assessed as increase in weight of prostate at 1 mg/kg, sc administered once daily for 4 days
AID296864Stimulation of prostate weight in castrated Sprague-Dawley rat2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators.
AID274619Selectivity for stimulation of levator ani muscle over prostate in sc dosed castrated Sprague-Dawley rat2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold.
AID292763Androgenic activity in castrated immature Sprague-Dawley rat assessed as ventral prostate weight stimulation at 5 mg/day, sc by Hersherberger assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgen receptor modulators.
AID706400Anabolic activity in sc dosed ORX rat model assessed as dose required to induce 50% effect on levator ani muscle weight administered 4 days2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Discovery of diarylhydantoins as new selective androgen receptor modulators.
AID291290Stimulation of ventral prostate tissue weight in Sprague-Dawley rat at 0.3 mg/kg, sc after 14 days2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications.
AID1128335Increase in levator ani muscle weight in orchidectomized Sprague-Dawley rat at 1 mg/kg, sc qd for 4 days relative to vehicle-treated control2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulators.
AID296857Stimulation of levator ani muscle weight in castrated immature Sprague-Dawley rat at 1 mg/day, sc2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators.
AID291292AUC(0-4h) in Sprague-Dawley rat at 10 mg/kg2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID291291Cmax in Sprague-Dawley rat at 10 mg/kg, po2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications.
AID705257Androgenic activity in ORX rat model assessed as weight of ventral prostate at 1 mg/kg/day, sc administered for 4 days2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1130861Myotrophic activity in castrate rat assessed as levator ani weight at 3 mg, sc qd for 7 days by autopsy analysis (Rvb = 23.6 +/- 1.08 mg)1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Syntheses and biological activities of 7 beta-methyl steroids.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID706411Transactivation of human androgen receptor transfected in human HeLa cells by luciferase reporter gene assay2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Discovery of diarylhydantoins as new selective androgen receptor modulators.
AID705255Androgenic activity in ORX rat model assessed as dose required for 50% activity on ventral prostate po administered for 4 days2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.
AID274614Stimulation of prostate growth in sc dosed castrated Sprague-Dawley rat2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold.
AID274615Inhibition of LH secretion in sc dosed castrated Sprague-Dawley rat2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold.
AID1130863Androgenic activity in castrate rat assessed as change in body weight at 3 mg, sc qd for 7 days by autopsy analysis (Rvb = 88 gram)1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Syntheses and biological activities of 7 beta-methyl steroids.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346888Human Androgen receptor (3C. 3-Ketosteroid receptors)2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (800)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990408 (51.00)18.7374
1990's4 (0.50)18.2507
2000's135 (16.88)29.6817
2010's196 (24.50)24.3611
2020's57 (7.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.02 (24.57)
Research Supply Index6.76 (2.92)
Research Growth Index6.53 (4.65)
Search Engine Demand Index140.37 (26.88)
Search Engine Supply Index2.52 (0.95)

This Compound (66.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (1.41%)5.53%
Reviews6 (0.71%)6.00%
Case Studies5 (0.59%)4.05%
Observational0 (0.00%)0.25%
Other827 (97.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]